Research Library

In Canada, research peptides are sold strictly for non-clinical laboratory use — not as approved drugs, supplements, or prescriptions — and are regulated under the Food and Drugs Act with Health Canada oversight.

In Canada, research peptides are sold as non-clinical laboratory chemicals — choosing a supplier means verifying per-batch HPLC purity, domestic shipping, research-use framing, and a reachable Canadian business.

BPC-157 is a synthetic pentadecapeptide derived from a gastric protein, with an extensive preclinical literature on tendon, ligament, and GI healing — concentrated in one research group and with limited independent human data.

Epithalon is a synthetic tetrapeptide from the Khavinson St. Petersburg programme with rodent data on telomerase and lifespan — independent replication is limited, and no longevity peptide has approved human use in Canada.

Growth hormone secretagogues come in two mechanistic families — GHRH analogues (sermorelin, CJC-1295, tesamorelin) acting on pituitary GHRH receptors and ghrelin receptor agonists (ipamorelin, GHRP-2, GHRP-6) acting on the GHSR — and only tesamorelin is Health Canada approved, for HIV lipodystrophy.

GHK-Cu is a copper-binding tripeptide first identified by Pickart in 1973, with a preclinical literature on fibroblast activation, collagen synthesis, and wound healing — widely used in cosmetics, and a research chemical in Canada for non-clinical use.

GLP-1 and multi-agonist peptides are the most researched class for metabolic outcomes — semaglutide and tirzepatide are Health Canada approved as drugs, while retatrutide remains investigational and non-approved analogues are sold only as research chemicals.